Published in Am J Health Syst Pharm on July 15, 2009
Safeguarding the process of drug administration with an emphasis on electronic support tools. Br J Clin Pharmacol (2013) 0.75
Acute cholecystitis: early versus delayed cholecystectomy, a multicenter randomized trial (ACDC study, NCT00447304). Ann Surg (2013) 5.12
Pharmacologic cholinesterase inhibition improves survival in experimental sepsis. Crit Care Med (2008) 2.18
Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40. Clin Pharmacol Ther (2003) 1.78
Medication and Treatment Adherence Following Hospital Discharge. Dtsch Arztebl Int (2016) 1.64
Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol (2005) 1.52
Fulminant hepatic failure: etiology and indications for liver transplantation. Nephrol Dial Transplant (2007) 1.39
Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther (2003) 1.39
Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother (2007) 1.27
Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol (2007) 1.26
Substandard anti-malarial drugs in Burkina Faso. Malar J (2008) 1.24
Upregulation of major histocompatibility complex class I on liver cells by hepatitis C virus core protein via p53 and TAP1 impairs natural killer cell cytotoxicity. J Virol (2003) 1.23
An orthotopic colon cancer model for studying the B7-H3 antitumor effect in vivo. J Gastrointest Surg (2006) 1.21
Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria. Eur J Clin Pharmacol (2004) 1.19
Assessing reported adherence to pharmacological treatment recommendations. Translation and evaluation of the Medication Adherence Report Scale (MARS) in Germany. J Eval Clin Pract (2010) 1.16
Successful strategy to improve the specificity of electronic statin-drug interaction alerts. Eur J Clin Pharmacol (2009) 1.14
Genome comparison of the epiphytic bacteria Erwinia billingiae and E. tasmaniensis with the pear pathogen E. pyrifoliae. BMC Genomics (2010) 1.12
Pilot study to assess the influence of an enhanced medication plan on patient knowledge at hospital discharge. Eur J Clin Pharmacol (2014) 1.10
Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro. J Pharmacol Exp Ther (2007) 1.09
Patients' beliefs about medicines in a primary care setting in Germany. J Eval Clin Pract (2010) 1.06
Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. Drug Metab Dispos (2006) 1.06
Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. J Antimicrob Chemother (2011) 1.04
Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy. Biochem Pharmacol (2009) 1.02
Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler®-based method. Eur J Clin Pharmacol (2011) 1.01
Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit. J Antimicrob Chemother (2008) 1.01
Are heat stroke and physical exhaustion underestimated causes of acute hepatic failure? World J Gastroenterol (2007) 1.00
Adenoviral B7-H3 therapy induces tumor specific immune responses and reduces secondary metastasis in a murine model of colon cancer. Oncol Rep (2007) 0.99
Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro. J Antimicrob Chemother (2011) 0.99
Modulation of cellular cholesterol alters P-glycoprotein activity in multidrug-resistant cells. Mol Pharmacol (2004) 0.99
Surgical treatment of primary hepatic epithelioid hemangioendothelioma. Transplantation (2005) 0.96
Early treatment of imported falciparum malaria in the intermediate and intensive care unit setting: an 8-year single-center retrospective study. Crit Care (2008) 0.95
Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks. Gastroenterology (2011) 0.94
Induction of multiple drug transporters by efavirenz. J Pharmacol Sci (2009) 0.93
Development and validation of a high-performance liquid chromatography assay for posaconazole utilizing solid-phase extraction. Clin Chem Lab Med (2008) 0.93
Prevention of intravenous drug incompatibilities in an intensive care unit. Am J Health Syst Pharm (2008) 0.92
Pharmacokinetics of linezolid in septic patients with and without extended dialysis. Eur J Clin Pharmacol (2009) 0.92
Impact of drug transporters on cellular resistance towards saquinavir and darunavir. J Antimicrob Chemother (2010) 0.91
Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro. Int J Antimicrob Agents (2013) 0.90
Moxifloxacin penetration into human gastrointestinal tissues. J Antimicrob Chemother (2004) 0.90
Ovarian stimulation affects the levels of regulatory endometrial NK cells and angiogenic cytokine VEGF. Am J Reprod Immunol (2011) 0.90
A prospective three-step intervention study to prevent medication errors in drug handling in paediatric care. J Clin Nurs (2014) 0.89
Evaluation of inhibitory potencies for compounds inhibiting P-glycoprotein but without maximum effects: f2 values. Drug Metab Dispos (2005) 0.89
Interaction of antiepileptic drugs with human P-glycoprotein in vitro. J Pharmacol Exp Ther (2003) 0.89
Low levels of prothrombin time (INR) and platelets do not increase the risk of significant bleeding when placing central venous catheters. Med Klin (Munich) (2009) 0.89
Prevention of adverse drug reactions in intensive care patients by personal intervention based on an electronic clinical decision support system. Intensive Care Med (2010) 0.88
Adverse drug reactions and deliberate self-poisoning as cause of admission to the intensive care unit: a 1-year prospective observational cohort study. Intensive Care Med (2008) 0.88
A single-center experience of 500 liver transplants using the modified piggyback technique by Belghiti. Liver Transpl (2009) 0.88
Recurrent herpes simplex virus hepatitis after liver retransplantation despite acyclovir therapy. Liver Transpl (2005) 0.88
Patients enrolled in randomised clinical trials are not representative of critically ill patients in clinical practice: observational study focus on tigecycline. Int J Antimicrob Agents (2013) 0.88
In vitro metabolism of the opioid tilidine and interaction of tilidine and nortilidine with CYP3A4, CYP2C19, and CYP2D6. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.87
Health care costs in the elderly in Germany: an analysis applying Andersen's behavioral model of health care utilization. BMC Health Serv Res (2014) 0.87
Lentiviral gene transfer ameliorates disease progression in Long-Evans cinnamon rats: an animal model for Wilson disease. Scand J Gastroenterol (2006) 0.87
Treatment of hepatitis C virus infection. World J Gastroenterol (2007) 0.87
Can a feedback report and training session on medication counseling for general practitioners improve patient satisfaction with information on medicines? Patient Prefer Adherence (2012) 0.87
Rule-based standardised switching of drugs at the interface between primary and tertiary care. Eur J Clin Pharmacol (2007) 0.86
Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro. Eur J Pharmacol (2013) 0.86
Impact of ATP-binding cassette transporters on human immunodeficiency virus therapy. Int Rev Cell Mol Biol (2010) 0.86
Living-donor liver transplantation: evaluation of donor and recipient. Nephrol Dial Transplant (2004) 0.86
Diagnostic criteria for acute liver failure due to Wilson disease. World J Gastroenterol (2007) 0.86
Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity. Eur J Clin Pharmacol (2012) 0.85
No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment. Antimicrob Agents Chemother (2010) 0.85
Knockdown of caveolin-1 decreases activity of breast cancer resistance protein (BCRP/ABCG2) and increases chemotherapeutic sensitivity. Naunyn Schmiedebergs Arch Pharmacol (2010) 0.84
Liver transplantation for hepatocellular carcinoma: is there evidence for expanding the selection criteria? Transplantation (2005) 0.84
No difference in genotype frequencies of polymorphisms of the nitric oxide pathway between Caucasian normal and high tension glaucoma patients. Mol Vis (2012) 0.84
Generation of inducible hepatitis C virus transgenic mouse lines. J Med Virol (2007) 0.84
CT and endoscopic ultrasound in comparison to endoluminal MRI: preliminary results in staging gastric carcinoma. Eur J Radiol (2008) 0.83
Dendritic cells can effectively be pulsed by HBVsvp and induce specific immune reactions in mice. Vaccine (2010) 0.83
Prioritising the prevention of medication handling errors. Pharm World Sci (2008) 0.83
Lack of evidence for association of high altitude pulmonary edema and polymorphisms of the NO pathway. High Alt Med Biol (2003) 0.83
Interaction of progestins with the human multidrug resistance-associated protein 2 (MRP2). Drug Metab Dispos (2005) 0.83
Reduction of saquinavir exposure by coadministration of loperamide: a two-way pharmacokinetic interaction. Clin Pharmacokinet (2004) 0.83
Sensitivity and specificity of plasma disappearance rate of indocyanine green as a prognostic indicator in acute liver failure. BMC Gastroenterol (2009) 0.83
Recurrence of clinically significant hepatitis A following liver transplantation for fulminant hepatitis A. J Clin Virol (2005) 0.82
Prophylaxis and treatment of recurrent viral hepatitis after liver transplantation. Nephrol Dial Transplant (2007) 0.82
Utilization of extended donor criteria in liver transplantation: a comprehensive review of the literature. Nephrol Dial Transplant (2007) 0.82
The A14-scale: development and evaluation of a questionnaire for assessment of adherence and individual barriers. Pharm World Sci (2009) 0.82
Tissue penetration of moxifloxacin into human gallbladder wall in patients with biliary tract infections. J Antimicrob Chemother (2009) 0.82
New coil concept for endoluminal MR imaging: initial results in staging of gastric carcinoma in correlation with histopathology. Eur Radiol (2006) 0.81
Differential modulation of the expression of important drug metabolising enzymes and transporters by endothelin-1 receptor antagonists ambrisentan and bosentan in vitro. Eur J Pharmacol (2011) 0.81
Interaction potential of etravirine with drug transporters assessed in vitro. Antimicrob Agents Chemother (2010) 0.81
Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766. J Clin Pharmacol (2007) 0.81
Development and evaluation of a computerised clinical decision support system for switching drugs at the interface between primary and tertiary care. BMC Med Inform Decis Mak (2012) 0.81
Varying linezolid susceptibility of vancomycin-resistant Enterococcus faecium isolates during therapy: a case report. J Antimicrob Chemother (2005) 0.81
Admission to intensive care for parasuicide by self-poisoning: variation by time cycles, climate and the lunar cycle. Psychiatry Res (2008) 0.81
Cellular uptake kinetics of bortezomib in relation to efficacy in myeloma cells and the influence of drug transporters. Cancer Chemother Pharmacol (2014) 0.80
Prevention of hepatitis B virus recurrence after liver transplantation. Clin Transplant (2006) 0.80
Posaconazole in intensive care patients I: invasive fungal infections in surgical intensive care and case presentation. Mycoses (2008) 0.80
Drug dose adjustments in patients with renal impairment. Am J Kidney Dis (2009) 0.80
Characteristics of medication schedules used by elderly ambulatory patients. Eur J Clin Pharmacol (2015) 0.80
Daily honey consumption does not change CYP3A activity in humans. J Clin Pharmacol (2010) 0.80
Association of liver stiffness with hepatic expression of pharmacokinetically important genes in alcoholic liver disease. Alcohol Clin Exp Res (2012) 0.79